Drug-Resistant Temporal Lobe Epilepsy Alters the Expression and Functional Coupling to Gαi/o Proteins of CB1 and CB2 Receptors in the Microvasculature of the Human Brain.
CB1 receptors
CB2 receptors
blood-brain barrier
drug-resistance
endocannabinoid system
mesial temporal lobe epilepsy
Journal
Frontiers in behavioral neuroscience
ISSN: 1662-5153
Titre abrégé: Front Behav Neurosci
Pays: Switzerland
ID NLM: 101477952
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
09
2020
accepted:
10
12
2020
entrez:
8
2
2021
pubmed:
9
2
2021
medline:
9
2
2021
Statut:
epublish
Résumé
Cannabinoid receptors 1 and 2 (CB1 and CB2, respectively) play an important role in maintaining the integrity of the blood-brain barrier (BBB). On the other hand, BBB dysfunction is a common feature in drug-resistant epilepsy. The focus of the present study was to characterize protein expression levels and Gαi/o protein-induced activation by CB1 and CB2 receptors in the microvascular endothelial cells (MECs) isolated from the brain of patients with drug-resistant mesial temporal lobe epilepsy (DR-MTLE). MECs were isolated from the hippocampus and temporal neocortex of 12 patients with DR-MTLE and 12 non-epileptic autopsies. Immunofluorescence experiments were carried out to determine the localization of CB1 and CB2 receptors in the different cell elements of MECs. Protein expression levels of CB1 and CB2 receptors were determined by Western blot experiments. [
Identifiants
pubmed: 33551765
doi: 10.3389/fnbeh.2020.611780
pmc: PMC7854549
doi:
Types de publication
Journal Article
Langues
eng
Pagination
611780Informations de copyright
Copyright © 2021 Nuñez-Lumbreras, Castañeda-Cabral, Valle-Dorado, Sánchez-Valle, Orozco-Suárez, Guevara-Guzmán, Martínez-Juárez, Alonso-Vanegas, Walter, Deli, Carmona-Cruz and Rocha.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Pharmacol Rev. 2005 Jun;57(2):173-85
pubmed: 15914466
Microvasc Res. 2020 Nov;132:104059
pubmed: 32798551
J Immunol. 2008 Nov 1;181(9):6406-16
pubmed: 18941231
J Neurosci Res. 2002 Mar 15;67(6):829-36
pubmed: 11891798
J Neurosci. 2012 Jun 27;32(26):8845-54
pubmed: 22745485
Neuromolecular Med. 2014 Sep;16(3):620-42
pubmed: 24929655
Front Behav Neurosci. 2020 May 06;14:52
pubmed: 32435186
Neurochem Int. 2007 Jan;50(1):219-28
pubmed: 16997427
Br J Pharmacol. 2008 Jan;153(2):299-308
pubmed: 17982478
Epilepsy Behav. 2015 Aug;49:13-6
pubmed: 25958228
Immunol Res. 2020 Jun;68(3):169-176
pubmed: 32542572
Brain Res Mol Brain Res. 2004 Dec 6;132(1):87-92
pubmed: 15548432
Neuroscientist. 2013 Jun;19(3):304-12
pubmed: 23072899
Inflamm Res. 2013 Aug;62(8):811-21
pubmed: 23722450
Neuroscience. 2014 Sep 26;277:455-73
pubmed: 25080160
J Cereb Blood Flow Metab. 2012 Jul;32(7):1207-21
pubmed: 22395208
Brain Res Bull. 2009 Jun 30;79(5):333-7
pubmed: 19480992
Epilepsia. 2018 Oct;59(10):1931-1944
pubmed: 30194729
Int Rev Neurobiol. 1996;39:197-221
pubmed: 8894848
Front Physiol. 2020 Jan 22;10:1583
pubmed: 32038280
J Neuroinflammation. 2018 May 14;15(1):142
pubmed: 29759062
Nature. 1993 Sep 2;365(6441):61-5
pubmed: 7689702
Nat Rev Drug Discov. 2008 May;7(5):438-55
pubmed: 18446159
Clin Endocrinol (Oxf). 2017 Mar;86(3):384-387
pubmed: 27651218
CNS Neurol Disord Drug Targets. 2020 Sep 16;:
pubmed: 32938356
Brain Pathol. 2011 Sep;21(5):544-57
pubmed: 21251115
Cardiovasc Res. 2010 Mar 1;85(4):773-84
pubmed: 19942623
Methods Mol Biol. 2016;1412:41-55
pubmed: 27245890
J Leukoc Biol. 2016 Apr;99(4):531-40
pubmed: 26467187
J Neuroimmune Pharmacol. 2006 Sep;1(3):223-36
pubmed: 18040800
Am J Physiol Heart Circ Physiol. 2016 Apr 1;310(7):H785-801
pubmed: 26825517
Exp Neurol. 2010 Jul;224(1):37-47
pubmed: 20353772
J Neurosci. 2012 Mar 21;32(12):4004-16
pubmed: 22442067
Curr Opin Neurol. 2015 Apr;28(2):130-5
pubmed: 25734953
Nature. 1990 Aug 9;346(6284):561-4
pubmed: 2165569
Cell Physiol Biochem. 2017;43(5):2088-2101
pubmed: 29059679